{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:45:33Z","timestamp":1761554733874,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"JSPS KAKENHI","award":["JP17K11577"],"award-info":[{"award-number":["JP17K11577"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.hfc.2019.11.002","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T17:16:22Z","timestamp":1581441382000},"page":"231-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Acute and Chronic Effects of Cancer Drugs on the Cardiovascular System"],"prefix":"10.1016","volume":"16","author":[{"given":"Shohei","family":"Moriyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Fukata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9974","key":"10.1016\/j.hfc.2019.11.002_bib1","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(14)61396-9","article-title":"40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: a population-based study","volume":"385","author":"Quaresma","year":"2015","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.hfc.2019.11.002_bib2","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.hfc.2019.11.002_bib3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hfc.2019.11.002_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jgo.2017.04.001","article-title":"Cardio-oncology in the older adult","volume":"8","author":"Reddy","year":"2017","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"7","key":"10.1016\/j.hfc.2019.11.002_bib5","first-page":"900","article-title":"Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients","volume":"32","author":"Johnson","year":"2016","journal-title":"Can J Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2019.11.002_bib6","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2019.11.002_bib7","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2901","article-title":"Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study","volume":"13","author":"Patnaik","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"15","key":"10.1016\/j.hfc.2019.11.002_bib8","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hfc.2019.11.002_bib9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","article-title":"Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study","volume":"32","author":"Armstrong","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hfc.2019.11.002_bib10","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2019.11.002_bib11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon Dennis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hfc.2019.11.002_bib12","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin adjuvant trial (BIG 1-01)","volume":"32","author":"De Azambuja","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.hfc.2019.11.002_bib13","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"31","key":"10.1016\/j.hfc.2019.11.002_bib14","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hfc.2019.11.002_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4048\/jbc.2016.19.4.402","article-title":"Breast cancer chemotherapy-induced left ventricular dysfunction in patients with breast cancer","volume":"19","author":"Yoon","year":"2016","journal-title":"J\u00a0Breast Cancer"},{"issue":"16","key":"10.1016\/j.hfc.2019.11.002_bib16","first-page":"e240","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.hfc.2019.11.002_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.008820","article-title":"ABCDE steps to prevent heart disease in breast cancer survivors","volume":"130","author":"Montazeri","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.hfc.2019.11.002_bib18","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","article-title":"Addition of ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive neuroectodermal tumor of bone","volume":"348","author":"Grier","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hfc.2019.11.002_bib19","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.1990.8.10.1664","article-title":"Multimodal therapy for the management of primary, nonmetastatic Ewing\u2019s sarcoma of bone: a long-term follow-up of the first intergroup study","volume":"8","author":"Nesbit","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hfc.2019.11.002_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002770000255","article-title":"Treatment of elderly patients with intermediate- and high-grade non-Hodgkin\u2019s lymphoma: a retrospective population-based study","volume":"80","author":"Peters","year":"2001","journal-title":"Ann Hematol"},{"issue":"19","key":"10.1016\/j.hfc.2019.11.002_bib21","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hfc.2019.11.002_bib22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hfc.2019.11.002_bib23","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hfc.2019.11.002_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11764-011-0186-6","article-title":"Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood","volume":"6","author":"Vandecruys","year":"2012","journal-title":"J\u00a0Cancer Surviv"},{"issue":"6","key":"10.1016\/j.hfc.2019.11.002_bib25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"Van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.hfc.2019.11.002_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy. clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.hfc.2019.11.002_bib27","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"3","key":"10.1016\/j.hfc.2019.11.002_bib28","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.hfc.2019.11.002_bib29","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jama.2015.12763","article-title":"Evaluation and treatment of pericarditis: a systematic review","volume":"314","author":"Imazio","year":"2015","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.hfc.2019.11.002_bib30","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/CIRCULATIONAHA.114.010376","article-title":"Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis","volume":"130","author":"Kyt\u00f6","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2019.11.002_bib31","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/petr.12062","article-title":"Pericardial effusion after pediatric hematopoietic cell transplant","volume":"17","author":"Aldoss","year":"2013","journal-title":"Pediatr Transplant"},{"issue":"5","key":"10.1016\/j.hfc.2019.11.002_bib32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bjh.13357","article-title":"Risk factors for pericardial effusion in adult patients receiving allogeneic haematopoietic stem cell transplantation","volume":"169","author":"Liu","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hfc.2019.11.002_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00246-017-1747-x","article-title":"Predictors and outcome of pericardial effusion after hematopoietic stem cell transplantation in children","volume":"39","author":"Versluys","year":"2018","journal-title":"Pediatr Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2019.11.002_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.bmt.1705023","article-title":"Pericardial effusion and cardiac tamponade in pediatric stem cell transplant recipients","volume":"36","author":"Rhodes","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hfc.2019.11.002_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bmt.2010.149","article-title":"Pericardial effusion post-SCT in pediatric recipients with signs and\/or symptoms of cardiac disease","volume":"46","author":"Neier","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hfc.2019.11.002_bib36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/bmt.2015.227","article-title":"Pericardial effusion post transplantation predicts inferior overall survival following allo-hematopoietic stem cell transplant","volume":"51","author":"Chen","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hfc.2019.11.002_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704144","article-title":"Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients","volume":"32","author":"Hahn","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hfc.2019.11.002_bib38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.critrevonc.2015.11.007","article-title":"Cardiovascular disease following hematopoietic stem cell transplantation: pathogenesis, detection, and the cardioprotective role of aerobic training","volume":"98","author":"Scott","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.hfc.2019.11.002_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-155-1-201107050-00004","article-title":"Cardiovascular hospitalizations and mortality among recipient of hematopoietic stem cell transplantation","volume":"155","author":"Chow","year":"2011","journal-title":"Ann Intern Med"},{"issue":"23","key":"10.1016\/j.hfc.2019.11.002_bib40","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2011-06-358226","article-title":"Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation","volume":"118","author":"Armenian","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hfc.2019.11.002_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbmt.2016.08.019","article-title":"National Institutes of Health hematopoietic cell transplantation late effects initiative: the Cardiovascular Disease and Associated Risk Factors Working Group report","volume":"23","author":"Armenian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.hfc.2019.11.002_bib42","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.hfc.2019.11.002_bib43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hfc.2019.11.002_bib44","first-page":"869","article-title":"Chemotherapy-induced cardiotoxicity: detection, prevention, and management","volume":"30","author":"Truong","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hfc.2019.11.002_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"23","key":"10.1016\/j.hfc.2019.11.002_bib46","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2013.01.090","article-title":"Cardiac complications of thoracic irradiation","volume":"61","author":"Jaworski","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.hfc.2019.11.002_bib47","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"Van Nimwegen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.hfc.2019.11.002_bib48","first-page":"1","article-title":"Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia","author":"Pasvolsky","year":"2015","journal-title":"Cardio Oncol"},{"issue":"13","key":"10.1016\/j.hfc.2019.11.002_bib49","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hfc.2019.11.002_bib50","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/bjh.14708","article-title":"A\u00a0retrospective analysis of 3954 patients in phase 2\/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma","volume":"178","author":"Laubach","year":"2017","journal-title":"Br J Haematol"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171361930114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155171361930114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:39:55Z","timestamp":1761554395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155171361930114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S155171361930114X"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2019.11.002","relation":{},"ISSN":["1551-7136"],"issn-type":[{"type":"print","value":"1551-7136"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute and Chronic Effects of Cancer Drugs on the Cardiovascular System","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2019.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}